NCT05522491 2025-12-11
Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer
Hebei Medical University Fourth Hospital
Phase 2 Not yet recruiting
Clinical Trials
3 trialsNCT06739395 2024-12-18
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Tianjin Medical University Second Hospital
Phase 2 Recruiting
NCT03057145 2021-09-02
Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Completed